However, breast cancers that co-express ERα and human epidermal growth factor receptor 2 (HER2), HER2 alone, or triple negative breast cancers (TNBC), which do not express any hormone or growth factor receptors, are more aggressive and tougher to treat. This evidence concerns the gene ESR1 and breast cancer.